Psyence Biomedical (PBM) Fundamental Analysis: Revenue, Earnings & Valuation

5.69 / 10

Netural

Fundamental score 5.69 (Neutral). Strengths include high accounts receivable turnover, strong interest coverage, and efficient inventory. Weaknesses are sluggish revenue growth, low fixed‑asset turnover, and modest cost‑of‑sales control. Overall fundamentals are selective.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score3/3

Weight47.66%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score0/3

Weight-10.23%

1M Return-2.75%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.71%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-2.68%

1M Return-0.65%

PB-ROE

Value0.07

Score1/3

Weight25.27%

1M Return5.22%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-6.09%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-5.02%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-3.02%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.97%

1M Return-0.74%

Asset-MV

Value-0.48

Score2/3

Weight59.79%

1M Return9.91%

Is PBM undervalued or overvalued?

PBM scores 5.69/10 on fundamentals and holds a Fair valuation at present. Backed by its -21.44% ROE, 0.00% net margin, -0.62 P/E ratio, 0.21 P/B ratio, and 97.62% earnings growth, these metrics solidify its Netural investment rating.